Johnson and Johnson Raises Dividend for 64th Consecutive Year

Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction) declared its 64th consecutive annual dividend increase on April 14, 2026, lifting its quarterly payout from $1.30 per share to $1.34 per share, a 3% increase. The new dividend is payable June 9, 2026 to shareholders of record as of May 26, 2026. For income investors, the raise arrives alongside a current yield of 3.2%, nearly double the healthcare sector average of 1.8%. That combination of yield and streak length makes this announcement worth examining closely.

A 64-Year Streak Signals Institutional Discipline

Six decades of uninterrupted dividend growth represents a financial commitment that has survived recessions, product liability crises, patent cliffs, and a global pandemic. Johnson & Johnson has raised its quarterly dividend from $0.46 per share in 2008 to $1.34 per share today, a trajectory that reflects consistent free cash flow generation and a management team that treats dividend growth as a core obligation to shareholders.

The recent progression reinforces that pattern. Johnson & Johnson raised its quarterly dividend from $1.19 in 2023 to $1.24 in 2024, then to $1.30 in 2025, and now to $1.34 in 2026. Each step reflects a deliberate, measured approach rather than a reactive one. CEO Joaquin Duato framed the broader momentum clearly in the Q1 2026 earnings release: “Johnson & Johnson had a strong start to 2026 and is delivering on its promise for a year of accelerated growth and impact.”

Yield Well Above the Sector Average

At a current yield of 3.2%, Johnson & Johnson offers income investors a return that exceeds the healthcare sector average of 1.8% by a meaningful margin. That gap matters in a sector where many high-growth names reinvest capital rather than return it. Johnson & Johnson does both. The company generated $1.5 billion in free cash flow in Q1 2026 alone, providing a clear foundation for the ongoing payout.

Johnson & Johnson also carries one of only two AAA credit ratings among U.S.-based companies, a distinction that reflects balance sheet strength well beyond what most dividend payers can claim. For investors seeking income with capital preservation characteristics, that credit profile adds a layer of confidence that yield figures alone cannot convey.

Analyst Target and Upside Context

With the stock trading at $241.01 and the analyst consensus price target sitting at $241.92, the implied price appreciation from current levels is modest. The investment case here rests primarily on income and business quality rather than near-term price appreciation. Analyst sentiment reflects that balanced view: 9 analysts rate the stock a Buy, 5 rate it a Strong Buy, and 10 carry a Hold rating, with no Sell ratings on record.

The stock trades at a trailing P/E of 22x and a forward P/E of 21x, reasonable multiples for a company guiding full-year 2026 adjusted EPS of $11.45 to $11.65 and revenue of $100.3 billion to $101.3 billion. Johnson & Johnson raised that guidance after delivering Q1 revenue of $24.062 billion, beating the consensus estimate of $23.614 billion, with adjusted EPS of $2.70 against a consensus of $2.6773.

Sustainability Supported by Portfolio Depth

The dividend increase comes despite real headwinds. STELARA revenue fell 60% in Q1 2026 as biosimilar competition took hold, creating roughly 920 basis points of drag on the Innovative Medicine segment. Johnson & Johnson absorbed that pressure and still beat estimates, a sign of genuine portfolio depth.

Growth drivers are filling the gap. DARZALEX generated $3.964 billion in Q1 revenue, up 23%. TREMFYA posted $1.608 billion, up 68%. CARVYKTI reached $597 million, up 62%. The MedTech segment added $8.636 billion in revenue, up 8%. The company also announced a $1 billion investment in a next-generation cell therapy manufacturing facility in Pennsylvania, pointing to long-term capacity being built to support future growth.

For dividend investors, the forward picture looks stable. Johnson & Johnson has demonstrated it can raise its payout through product transitions, litigation charges, and macro uncertainty alike. With a 3.2% yield, a 64-year streak, and a pipeline generating multiple new approvals in a single quarter, the structural case for continued dividend growth remains intact.